Key Highlights

  • Up 50.00 per cent over six months and 31.55 per cent over three months, the strongest medium-term record of the eight.
  • Stochastic of 94.59 on %K against 96.19 on %D, the most extended reading in the group.
  • Commodity Channel index of 94.88 sits below the 100 line, one of only two in the group to do so.

Technical position

RSI 14 reads 60.54 with a Buy technical rating and a Strong buy Moving Average rating, while the oscillator group reads Neutral. The stochastic is the most stretched in its peer group, at 94.59 on %K against 96.19 on %D, with the slower line sitting above the faster one. The Commodity Channel Index reads 94.88, below the 100 line and one of only two in the group under that level. Momentum over ten periods reads 0.75 and the Awesome Oscillator 0.16. The 21-period exponential moving average holds above the 50-period average.

Fundamental snapshot

Evolent Health sits in commercial services with a Market Capitalisation of USD 556.25 million. The shares last traded at USD 4.92, up 0.61 per cent on the session. Trailing Diluted Earnings per Share is negative at USD 4.57, so no price to earnings ratio applies. The reported earnings per share growth figure of -184.71 per cent reflects a percentage change across a sign flip rather than an underlying rate. No Dividend is paid. Analyst consensus reads Strong buy.

Price performance

The stock is up 6.26 per cent over one week, 15.49 per cent over one month, 31.55 per cent over three months and 50.00 per cent over six months, with a 22.69 per cent gain year to date. It is down 49.28 per cent over one year and 72.67 per cent on an all time basis. One month Volatility of 8.85 per cent is the highest in its peer group.

This article is general information only and does not take into account any individual objectives, financial situation or needs. It is not a recommendation to buy, sell or hold any security. All details are as stated in the company announcement or third party research referenced and are subject to change. Past performance is not a reliable indicator of future performance. Investors should consider the appropriateness of any information having regard to their own circumstances and seek independent financial advice before making any financial decision.